



# CLX Investment Company, Inc.

(OTC BB: CLXN)

29970 Technology Drive, Suite 203, Murrieta, CA 92563

Telephone: (951) 677-6735 / Facsimile: (951) 677-6573

investors@clxinvestments.com

www.clxinvestments.com

## November 2007 Newsletter

### CLX Investment Company Signs Amended Letter of Intent and Plans to Acquire Remaining Ownership Percentage of Zonda, Incorporated

#### Inside This Issue

*Vera Leonard Appointed as New CEO for CLX Investments*

**Page 2**

*CEO Greeting*

**Page 3**

*Hunter Wise Financial Group Selected as Investment Banking Firm For Dalian Chuming Group Reverse Merger Transaction*

**Page 3**

#### About the Company

CLX Investment Company, Inc. (OTC BB: CLXN) is a holding company seeking to provide long-term value for its shareholders by executing an acquisition strategy.

CLX owns a 51% equity interest in Zonda, Incorporated ([www.zondaincusa.com](http://www.zondaincusa.com)), a developer and manufacturer of unique diagnostic tests for both the medical and non-medical markets. The Company has announced an agreement to acquire the remaining 49% of Zonda and make this subsidiary a major focus of CLX's operations.

CLX also holds a common stock position in ActionView International, Inc. ([www.actionviewinternational.com](http://www.actionviewinternational.com)), a publicly traded company that designs, develops, and manufactures vividly illuminated motion billboards.

**C**CLX Investment Company (stock symbol OTC BB: CLXN), which recently acquired an additional 51% of Zonda, Incorporated, a developer and manufacturer of unique diagnostic tests for the medical and non-medical markets, has reaffirmed its intention to acquire the remaining 49% of Zonda's issued and outstanding shares and outlined the process that this acquisition is expected to follow.

The acquisition of a majority ownership percentage has positioned Zonda to become a major focus of the company's operations, and purchase of the remaining percentage is tied to Zonda meeting specific milestones.

An amended letter of intent was entered into by the two companies at the time of the purchase of the last 5% that gave CLX a majority interest in Zonda. The amended letter of intent includes a provision under which an escrow will be established, and the shares of CLX and Zonda to be exchanged for CLX to own 100% of Zonda will be deposited into the escrow. Once certain milestones are achieved, the exchange would be effected, and Zonda would become a wholly owned subsidiary of CLX.

The escrow will be established and the shares of both companies will be deposited into the escrow once the definitive agreement has been signed.

Since mid-August 2007, CLX has increased its ownership of Zonda with the acquisition of an additional 20% of Zonda's issued and outstanding shares, raising its current equity position from 41% to 51%.

"The escrow will allow CLX to ensure that certain critical milestones are reached before the balance of Zonda is purchased and CLX becomes the majority owner of Zonda," said Steven R. Peacock, consultant CEO of CLX Investment Company. "We continue to be enthusiastic about the potential of Zonda in the public markets and look forward to the definitive agreement that will allow our acquisition of Zonda to move forward."

Zonda's tests utilize proprietary technology that detects enzymes that are specific to the target microorganisms. The Zonda medical diagnostic tests are ideal for the clinical laboratory, point of care, and the over-the-counter (OTC) markets.

Zonda's intellectual property position in enzymatic detection technology will

(continued on page 2)

## Management Transition Initiated for CLX with Appointment of Vera Leonard as CEO

### Resignation of Steven R. Peacock as Consultant CEO Signals New Focus on Medical Diagnostic Testing Products

CLX Investment Company announced a management transition during which consultant CEO Steven R. Peacock stepped down from that position and Zonda chief executive officer Vera Leonard was appointed to the position of president and chief executive officer of CLX.

Ms. Leonard possesses considerable successful experience in leadership positions with major medical manufacturing and distribution companies and has served as CEO of Zonda, Inc. since August of 2007.

With CLX's recent acquisition of a majority percentage of Zonda and the planned acquisition of the remaining 49% of its issued and outstanding shares, Ms. Leonard is considered to be the ideal person to lead CLX with Zonda operating as a subsidiary.

"Vera Leonard is uniquely qualified to lead CLX now that the medical diagnostic testing space has been positioned as the focus of the company's operations," stated Mr. Peacock.

"CLX's Board of Directors has appointed her to the president/CEO position effective November 1st, and I am pleased to be stepping aside so that Vera can take the reins of the company and implement her vision of how CLX should be developed to deliver value to the company's shareholders.

"In her role as CEO of Zonda, Vera has conducted a thorough evaluation of the company's current operations and now has the ability to speak authoritatively on all aspects of its business. We look forward to her leadership of the public company and hope that shareholders will continue to follow the progress of CLX and its majority owned subsidiary, Zonda, Inc., under Vera's guidance," Mr. Peacock added.


On November 1, 2007, a Current Report on Form 8-K with the details of this appointment was filed with the Securities and Exchange Commission.

The 8-K reported that at a recent meeting of the Board of Directors, Vera Leonard was appointed to the position of president and chief executive officer to fill the vacancy created by the recent resignations of Steven R. Peacock as consultant chief executive officer and Robert McCoy as president. Mr. McCoy will remain in his position as chairman of the Board of Directors.

"Ms. Leonard has already made tremendous strides within Zonda, and we believe that she is the right person to lead CLX as it seeks to deliver long term value to the company's

## Amended Letter of Intent Outlines Plans for Acquisition of Remaining Ownership Percentage of Zonda

(continued from page 1)



give the company a unique position in the clinical diagnostic market where there is increasing need for simple, reliable, and cost-effective rapid point of care diagnostic tests.

The company's first medical test for Chlamydia is currently sold throughout Europe under the HandiLab brand, and a U.S. launch is being planned. Zonda believes it will compete successfully with all current technologies, including the "gold standard" nucleic acid amplification testing (NAAT) technology, while offering several enhanced features.

shareholders," stated Mr. McCoy. "Ms. Leonard's significant experience in the medical diagnostic testing industry provides the opportunity for CLX to not only maximize the potential value of Zonda, but to also explore opportunities to target additional medical testing technologies that can be developed as assets for the public company."

Ms. Leonard commented, "I am pleased to accept the appointment to the position of president/CEO of CLX Investment Company and look forward to working with the Board to execute the company's business strategy. I intend to address CLX shareholders in the very near future on specific issues related to Zonda and how we expect to grow this subsidiary in the medical diagnostic testing market."

As vice president of U.S. sales for a Nasdaq listed company that specializes in rapid, point of care diagnostic tests, Ms. Leonard led negotiations on agreements that added approximately \$8 million in annual revenue and helped to grow revenues from \$32 million to \$51 million in 3 years. She delivered an unprecedented 6 consecutive quarters of financial performance that met or exceeded expectations and saved more than \$1,500,000 annually for the company from renegotiations of a growth incentive plan, implementation of net pricing strategy and elimination of GPO administration fees.

Additional biographical information on Ms. Leonard is included in the 8-K filing.

### Safe Harbor Statement

All statements included in this release, including statements regarding potential future plans and objectives of CLX Investments are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Investments' control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.

## ActionView International Announces the Selection of Hunter Wise Financial Group to Act as Investment Banking Firm For Dalian Chuming Group Reverse Merger Transaction

ActionView International, Inc., in which CLX Investment Company holds a common stock position, recently announced that Dalian Chuming Group Co., LTD, a major producer of fresh and frozen pork and other processed meat products in China, has selected Hunter Wise Financial Group, LLC of Irvine, California to act as the exclusive investment banking firm for its reverse merger into the U.S. public markets. ActionView International has been positioned to serve as the public vehicle for the reverse merger transaction.

Hunter Wise Financial Group and its wholly owned Broker/Dealer, Hunter Wise Securities, LLC, a FINRA and SIPC member firm, provides investment banking services including institutional finance, financial advisory services, international transactions, and mergers, acquisitions and divestitures.

Dalian Chuming Group has engaged Hunter Wise Financial Group to act as its exclusive financial advisor, and Hunter Wise Securities to act as the exclusive placement agent in connection with its pursuit of a U.S. public listing.

Rick Mari, director and chief executive officer of ActionView International, commented, "We are pleased that Dalian Chuming Group has selected a firm of the caliber of Hunter Wise to provide investment banking services for its planned reverse merger into ActionView International, and we look forward to this transaction progressing to its close."

ActionView International has entered into a binding agreement to serve as the public vehicle for the Dalian Chuming reverse merger that outlines the terms of the transaction, which includes a stock position for current ActionView shareholders and a cash payment for the purchase of the public company. As part of the agreement between the parties, ActionView is providing a financing component for the reverse merger transaction. Currently, ActionView has funded over 80% of its financing commitment.

Under terms of the agreement, ActionView is expected to exchange a specified percentage of its total issued and outstanding capital stock in exchange for all of Dalian Chuming's issued and outstanding shares. In addition to the base percentage, ActionView shareholders will retain another three times the value of the amount of the funding it has provided in equity of the new public company.

Dalian Chuming Group is among a select group of industrialized farming corporations in northeastern China and is known for its international quality management standards and global safety certifications. Dalian Chuming is the second largest meat producer in China's Northeast Region, which has a population of 108 million. The pursuit of a U.S. public listing is expected to allow the Chuming Group to expand into additional geographic markets.

## Greetings from the CEO

This is my last CEO greeting to CLX Investment Company shareholders, since I resigned that position effective November 1, 2007, and Vera Leonard, who was brought in to lead CLX with a focus on the medical diagnostic testing market, was appointed to serve as President and CEO of CLX by the Board of Directors. Future CEO greetings will be authored by Ms. Leonard and in the near term, will be focused on the operations of Zonda, Incorporated.

As I expressed in the press release announcing my resignation from the CLX management team, there is no one more qualified to lead CLX with its new focus than Vera Leonard, and we look forward to the future of CLX and Zonda under her leadership.

Management's goal since CLX withdrew its election to be regulated as a business development company (BDC) and transitional management was installed was to execute an acquisition strategy designed to deliver long-term value to shareholders. The planned acquisition of 100% of the issued and outstanding shares of Zonda, Incorporated is a critical aspect of this plan.

As important a milestone as the acquisition of Zonda is, there is a broader business strategy that will be articulated by Ms. Leonard in the near future that is expected to increase the potential upside for CLX shareholders. We are pleased that CLX is now positioned so that the acquisition strategy it has undertaken can begin showing its potential long-term value utilizing the expertise and experience of Ms. Leonard.

Javelin Advisory Group will continue to support CLX's efforts with its work related to financial reporting and SEC filing compliance and in any advisory capacity requested by CLX management.

I hope that CLX shareholders will provide the same level of support to Ms. Leonard as they have to former management through the company's transitional period. As always, they are encouraged to maintain communication with the company though the appropriate shareholder communication telephone number and email address.

Regards,

Steven R. Peacock  
Consultant CEO Emeritus